PYXS stock news · Pyxis Oncology
Get alerts for PYXS
Follow Pyxis Oncology (PYXS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PYXSFree on the App Store and Google Play, or on the web.
Pyxis Oncology shared new Phase 1 results for micvotabart pelidotin, showing a 39% response rate in head and neck cancer patients.
Good for PYXSPyxis Oncology reported a 39% confirmed response rate and plans a global Phase 3 study for MICVO. These results support progress, but are still from Phase 1.
12 health care companies are seeing big changes in their stock prices today.
NeutralPyxis Oncology shares fell 25% to $2.18. The article gives no company news explaining the move, so it does not change the business outlook.
12 health care companies are changing prices before the market opens on Wednesday.
NeutralThe report says PYXS shares fell 13.8%, but gives no company news or reason for the drop. That alone does not show a change in its business outlook.
An analyst points out important safety issues with Pyxis Oncology's cancer drug.
NeutralPyxis released Phase 1 efficacy and safety data showing strong responses and also high severe side effects; I read this as neutral for Pyxis.